Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Oberste

Sports Medicine Tallahassee, FL Medical Doctor

NPI 1609860451 CMS profile 380346

3334 Capital Medical Blvd, Suite 400, Tallahassee, FL 32308

Open in the dashboard

General payments

$62,006

314 records reported · program years 2019–2025

Research payments

$5,219

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Oberste of Tallahassee, FL is reported in the CMS Open Payments database as having received $62,006 across 314 general payments and $5,219 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,769 44
2024 General $13,423 62
2023 General $10,481 72
2022 General $4,909 23
2021 General $6,851 42
2020 General $7,786 34
2020 Research $5,219 3
2019 General $7,788 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Oberste
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to David Oberste were reported at $10,769. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year David Oberste Sports Medicine median Middle half National median
2019 $7,788 $1,176 $199–$4,249 $163
2020 $7,786 $708 $96–$2,890 $114
2021 $6,851 $1,213 $152–$3,994 $132
2022 $4,909 $1,230 $159–$3,998 $149
2023 $10,481 $584 $146–$2,836 $160
2024 $13,423 $628 $163–$3,168 $164
2025 $10,769 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CGG Medical Inc $29,923 63 payments
  2. Arthrex, Inc. $24,774 202 payments
  3. Smith+Nephew, Inc. $2,604 23 payments
  4. Zimmer Biomet Holdings, Inc. $2,483 14 payments
  5. Stryker Corporation $1,810 4 payments
  6. Miach Orthopaedics, Inc. $130 1 payment
  7. Avanos Medical $121 1 payment
  8. DePuy Synthes Sales Inc. $68 1 payment
  9. Linvatec Corporation $40 1 payment
  10. Pacira Pharmaceuticals Incorporated $21 1 payment
  11. Other $33 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $27,770 81 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,040 8 payments
  3. Food and Beverage $9,497 217 payments
  4. Education $8,700 8 payments
Products named General payments · program years 2019–2025
  1. Q-FIX $1,787 8 payments
  2. Bone Anchors with Arthroscopic Delivery System $1,068 5 payments
  3. Persona $999 5 payments
  4. SALVATION $944 2 payments
  5. HEALICOIL $919 4 payments
  6. NA $694 1 payment
  7. ROSA $373 5 payments
  8. INSPACE $173 1 payment
  9. SPATIAL FRAME $149 1 payment
  10. FIRSTPASS $149 1 payment
  11. Other $1,509 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Exactech, Inc. $5,219 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

202

Median for Sports Medicine: 144

Drug cost

$2,917

Median for Sports Medicine: $1,027

Branded share of claims

17.8%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 11 $1,664
Meloxicam Generic 115 $752
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $252
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $144
Amoxicillin Generic 40 $105

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$133,546

Of which drugs: $519

Medicare patients

206

Average age 75

Services billed

817

134 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 26%
Ischemic heart disease 25%
Cancer 20%
Chronic kidney disease 17%
Depression 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 32 267 $186

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

317 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record